世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

バソプレシン拮抗薬市場（用途：中枢性糖尿病性消耗品、腎性糖尿病性消耗品、その他の用途）-世界の産業分析、サイズ、シェア、成長、トレンド、および予測、2023-2031年


Vasopressin Antagonists Market (Application: Central Diabetes Insipidus, Nephrogenic Diabetes Insipidus, and Other Applications) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

バソプレシン拮抗薬市場 - レポートの範囲 TMRの調査レポート「バソプレシン拮抗薬の世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ 		2023年3月27日 US$5,795
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		160 英語

　

サマリー

バソプレシン拮抗薬市場 - レポートの範囲
TMRの調査レポート「バソプレシン拮抗薬の世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として考慮し、2017年から2031年までの世界のバソプレッシン拮抗薬市場の収益を提供します。また、2023年から2031年までの世界のバソプレシン拮抗薬市場の複合年間成長率（CAGR %）を掲載しています。

本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行いました。二次調査では、バソプレシン拮抗薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、および関連文書を参照しました。

また、インターネット上の情報源、政府機関の統計データ、ウェブサイト、業界団体なども二次調査の対象とした。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界のバソプレシン拮抗薬市場のさまざまな属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界のバソプレシン拮抗薬市場における競争力学の変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界のバソプレシン拮抗薬市場への参入に関心のある企業にとっても貴重なツールになります。

本レポートは、世界のバソプレシン拮抗薬市場の競争環境について掘り下げています。世界のバソプレシン拮抗薬市場で活動する主要企業が特定され、これらの各企業は様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のバソプレシン拮抗薬市場のプレイヤーの属性です。

世界のバソプレシン拮抗薬市場レポートで回答された主要な質問
- 予測期間中に全地域でバソプレシン拮抗薬が生み出した売上/収益はどのくらいですか？
- 世界のバソプレシン拮抗薬市場におけるビジネスチャンスは？
- 市場における主な推進要因、阻害要因、機会、脅威は何か？
- 予測期間中に最も速いCAGRで拡大するのはどの地域市場か？
- 2031年に世界で最も高い収益を上げると予測されるセグメントは？
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか？
- 世界市場で事業展開している各社の市場ポジションは？

バソプレシン拮抗薬市場 - 研究目的と研究アプローチ
バソプレッシン拮抗薬の世界市場に関する包括的なレポートは、概要から始まり、研究の範囲と目的へと続きます。本調査の目的、市場で活動する主要ベンダーや流通業者、製品承認のための規制シナリオについて詳しく解説しています。

読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。

本レポートでは、バソプレシン拮抗薬の世界市場を製品、エンドユーザー、地域の観点で分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界のバソプレシン拮抗薬市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vasopressin Antagonists Market
4. Market Overview
    4.1. Introduction
        4.1.1. Drug Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Vasopressin Antagonists Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Disease Incidence and Prevalence
    5.3. Regulatory Approval
    5.4. COVID-19 Impact Analysis
6. Global Vasopressin Antagonists Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Type, 2017–2031
        6.3.1. Vaprisol
        6.3.2. Tolvaptan
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global Vasopressin Antagonists Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Central Diabetes Insipidus
        7.3.2. Nephrogenic Diabetes Insipidus
        7.3.3. Other Applications
    7.4. Market Attractiveness Analysis, by Application
8. Global Vasopressin Antagonists Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Retail Pharmacies
        8.3.2. Hospital Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Vasopressin Antagonists Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Vasopressin Antagonists Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Type, 2017–2031
        10.2.1. Vaprisol
        10.2.2. Tolvaptan
    10.3. Market Value Forecast, by Application, 2017–2031
        10.3.1. Central Diabetes Insipidus
        10.3.2. Nephrogenic Diabetes Insipidus
        10.3.3. Other Applications
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Retail Pharmacies
        10.4.2. Hospital Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Type
        10.6.2. By Application
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Vasopressin Antagonists Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2017–2031
        11.2.1. Vaprisol
        11.2.2. Tolvaptan
    11.3. Market Value Forecast, by Application, 2017–2031
        11.3.1. Central Diabetes Insipidus
        11.3.2. Nephrogenic Diabetes Insipidus
        11.3.3. Other Applications
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Retail Pharmacies
        11.4.2. Hospital Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Spain
        11.5.5. Italy
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Type
        11.6.2. By Application
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Vasopressin Antagonists Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2017–2031
        12.2.1. Vaprisol
        12.2.2. Tolvaptan
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Central Diabetes Insipidus
        12.3.2. Nephrogenic Diabetes Insipidus
        12.3.3. Other Applications
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Retail Pharmacies
        12.4.2. Hospital Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Type
        12.6.2. By Application
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Vasopressin Antagonists Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2017–2031
        13.2.1. Vaprisol
        13.2.2. Tolvaptan
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Central Diabetes Insipidus
        13.3.2. Nephrogenic Diabetes Insipidus
        13.3.3. Other Applications
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Retail Pharmacies
        13.4.2. Hospital Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Type
        13.6.2. By Application
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Vasopressin Antagonists Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Type, 2017–2031
        14.2.1. Vaprisol
        14.2.2. Tolvaptan
    14.3. Market Value Forecast, by Application, 2017–2031
        14.3.1. Central Diabetes Insipidus
        14.3.2. Nephrogenic Diabetes Insipidus
        14.3.3. Other Applications
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Retail Pharmacies
        14.4.2. Hospital Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Type
        14.6.2. By Application
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company, 2022
    15.3. Company Profiles
        15.3.1. Otsuka
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Test Drug Type Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Cumberland Pharmaceuticals
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Test Drug Type Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Mayo Clinic
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Test Drug Type Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Hopital du Sacre-Coeur de Montreal
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Test Drug Type Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview

ページTOPに戻る



図表リスト

List of Tables

Table 1: Global overview of Vasopressin Antagonists

Table 2: Regional overview of Vasopressin Antagonists

Table 3: North America Overview of Vasopressin Antagonists

Table 4: APAC overview of Vasopressin Antagonists

Table 5: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 6: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 7: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 8: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 9: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 10: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 11: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 12: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Europe Vasopressin Antagonists Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 15: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 19: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 23: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 27: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 28: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

　

ページTOPに戻る


　

Summary

Vasopressin Antagonists Market – Scope of Report
TMR’s report on the global vasopressin antagonists market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global vasopressin antagonists market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vasopressin antagonists market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the vasopressin antagonists market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vasopressin antagonists market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global vasopressin antagonists market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vasopressin antagonists market.

The report delves into the competitive landscape of the global vasopressin antagonists market. Key players operating in the global vasopressin antagonists market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global vasopressin antagonists market profiled in this report.

Key Questions Answered in Global Vasopressin Antagonists Market Report
• What is the sales/revenue generated by vasopressin antagonists across all regions during the forecast period?
• What are the opportunities in the global vasopressin antagonists market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Vasopressin Antagonists Market – Research Objectives and Research Approach
The comprehensive report on the global vasopressin antagonists market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global vasopressin antagonists market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global vasopressin antagonists market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vasopressin Antagonists Market
4. Market Overview
    4.1. Introduction
        4.1.1. Drug Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Vasopressin Antagonists Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Disease Incidence and Prevalence
    5.3. Regulatory Approval
    5.4. COVID-19 Impact Analysis
6. Global Vasopressin Antagonists Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Type, 2017–2031
        6.3.1. Vaprisol
        6.3.2. Tolvaptan
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global Vasopressin Antagonists Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Central Diabetes Insipidus
        7.3.2. Nephrogenic Diabetes Insipidus
        7.3.3. Other Applications
    7.4. Market Attractiveness Analysis, by Application
8. Global Vasopressin Antagonists Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Retail Pharmacies
        8.3.2. Hospital Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Vasopressin Antagonists Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Vasopressin Antagonists Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Type, 2017–2031
        10.2.1. Vaprisol
        10.2.2. Tolvaptan
    10.3. Market Value Forecast, by Application, 2017–2031
        10.3.1. Central Diabetes Insipidus
        10.3.2. Nephrogenic Diabetes Insipidus
        10.3.3. Other Applications
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Retail Pharmacies
        10.4.2. Hospital Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Type
        10.6.2. By Application
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Vasopressin Antagonists Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2017–2031
        11.2.1. Vaprisol
        11.2.2. Tolvaptan
    11.3. Market Value Forecast, by Application, 2017–2031
        11.3.1. Central Diabetes Insipidus
        11.3.2. Nephrogenic Diabetes Insipidus
        11.3.3. Other Applications
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Retail Pharmacies
        11.4.2. Hospital Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Spain
        11.5.5. Italy
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Type
        11.6.2. By Application
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Vasopressin Antagonists Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2017–2031
        12.2.1. Vaprisol
        12.2.2. Tolvaptan
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Central Diabetes Insipidus
        12.3.2. Nephrogenic Diabetes Insipidus
        12.3.3. Other Applications
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Retail Pharmacies
        12.4.2. Hospital Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Type
        12.6.2. By Application
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Vasopressin Antagonists Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2017–2031
        13.2.1. Vaprisol
        13.2.2. Tolvaptan
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Central Diabetes Insipidus
        13.3.2. Nephrogenic Diabetes Insipidus
        13.3.3. Other Applications
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Retail Pharmacies
        13.4.2. Hospital Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Type
        13.6.2. By Application
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Vasopressin Antagonists Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Type, 2017–2031
        14.2.1. Vaprisol
        14.2.2. Tolvaptan
    14.3. Market Value Forecast, by Application, 2017–2031
        14.3.1. Central Diabetes Insipidus
        14.3.2. Nephrogenic Diabetes Insipidus
        14.3.3. Other Applications
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Retail Pharmacies
        14.4.2. Hospital Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Type
        14.6.2. By Application
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company, 2022
    15.3. Company Profiles
        15.3.1. Otsuka
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Test Drug Type Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Cumberland Pharmaceuticals
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Test Drug Type Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Mayo Clinic
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Test Drug Type Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Hopital du Sacre-Coeur de Montreal
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Test Drug Type Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview

ページTOPに戻る



List of Tables/Graphs

List of Tables

Table 1: Global overview of Vasopressin Antagonists

Table 2: Regional overview of Vasopressin Antagonists

Table 3: North America Overview of Vasopressin Antagonists

Table 4: APAC overview of Vasopressin Antagonists

Table 5: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 6: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 7: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 8: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 9: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 10: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 11: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 12: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Europe Vasopressin Antagonists Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 15: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 19: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 23: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 27: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 28: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

Transparency Market Research 社の最新刊レポート

本レポートと同じKEY WORD（analysis size）の最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ（Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/30　10:25

143.73 円

160.93 円

195.03 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.